Home/Pipeline/SBX 1968

SBX 1968

Prostate Cancer

Early-stage ClinicalActive

Key Facts

Indication

Prostate Cancer

Phase

Early-stage Clinical

Status

Active

Company

Stramsen Biotech

About Stramsen Biotech

Stramsen Biotech is an early-stage, private biotech firm pioneering a plant-based drug discovery and development platform. It boasts a robust pipeline of 33 drug candidates, with 11 in early-stage clinical trials, targeting major therapeutic areas including oncology, cardiovascular disease, HIV, and diabetes. The company claims a $19 billion valuation from a third-party appraisal and is backed by lead investor GEM Global Yield LLC SCS, positioning it for significant growth as it advances candidates toward FDA submissions.

View full company profile

Therapeutic Areas

Oncology Cardiovascular Diseases Infectious Disease (HIV)Metabolic Disorders (Diabetes)Neurological Disorders Musculoskeletal Disorders (Arthritis)Urology Wound Care Nephrology

Other Prostate Cancer Drugs

Drug	Company	Phase	Status
APVO442	Aptevo Therapeutics	Preclinical	Active
APVO452	Aptevo Therapeutics	Discovery	Active
BIO 300	Humanetics Corp.	Not Specified	Active
Opaganib	RedHill Biopharma	Phase 2	Active
MagSense™ PSMA Imaging Agent	Imagion Biosystems	Pre‑clinical	Active
Small-Molecule Therapeutic	AIkido Labs	Pre-clinical	Active
Leronlimab	CytoDyn	Preclinical	Phase in progress
CROES Registry	AngioDynamics	Post-Market Registry	Active
Cannabics® PRST-33	CNBX Pharmaceuticals	Discovery	In vitro POC
HDP-103	Heidelberg Pharma	Preclinical	Active
ENV105	Kairos Pharma	Phase 2	Active
AI for Prostate Cancer	Invenio Imaging	Research	Active